AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00357422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ethanol injection therapy
Description: 99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
Study NCT01249963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Atémpero
Description: T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
Study NCT01249963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlitraQ (Abbott)
Description: AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
Study NCT03174613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC51-0255
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Study NCT03174613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Study NCT01095341 — intervention group
Intervention type: OTHER
Intervention: No intervention performed
Study NCT00738829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage.
Study NCT00738829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
Study NCT00738829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage.
Study NCT02646150 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Perfusion Imaging
Study NCT03803202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
Study NCT02278315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Single IV dose of I-131-CLR1404, increased/decreased by cohort
Study NCT03803202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Participants received a single dose of PCV13 intramuscularly.
Study NCT03803202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Participants received a single dose of PPSV23 intramuscularly.
Study NCT02224638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraHoney HD
Description: Honey
Study NCT02224638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SkinTegrity
Description: Hydrogel
Study NCT02994095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot Study
Description: Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
Study NCT00722709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
Study NCT00722709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal.
Study NCT02807844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study NCT02278315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg dexamethasone orally once weekly for up to 12 weeks
Study NCT02278315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
Study NCT00750230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM
Description: see Treatment Arm
Study NCT02807844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study NCT01553071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) plus Intravenous Safingol
Description: A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects.
Study NCT01198821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (g/kg/day)
Description: Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
Study NCT01198821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (mg/m²)
Description: Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
Study NCT03154671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management
Description: Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
Study NCT04631315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate Ophthalmic Emulsion 0.05%
Description: 1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
Study NCT04631315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
Description: 1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
Study NCT04188990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional dietary intervention
Description: The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
Study NCT04188990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: By demand
Description: In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now
Study NCT04188990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual current care
Description: In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide
Study NCT04131985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spina Block
Description: After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
Study NCT03487393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic facial nerve stimulation
Description: Magnetic stimulation of facial nerve.
Study NCT02584413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: -Standard of care
Study NCT02584413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium contrast
Description: -Standard of care
Study NCT03788863 — intervention group
Intervention type: DRUG
Intervention: Diflucortolone valerate (BAY866146)
Description: Follow clinical administration
Study NCT03663140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection
Description: GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
Study NCT00776321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome
Study NCT02537730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioclean MPS VII
Description: PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
Study NCT02537730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aosept Clearcare
Description: Hydrogen Peroxide Disinfecting and Cleaning system
Study NCT02537730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens
Study NCT00710892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allodepleted T Cells
Description: Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity.
Study NCT00532701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 16 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16
Study NCT00532701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + LD RBV for 16 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16
Study NCT00532701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 24 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24
Study NCT00925093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
Study NCT00925093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
Study NCT00925093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
Study NCT01434030 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
Study NCT01995474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twisted Syringe
Description: briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
Study NCT01995474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Technique
Description: syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
Study NCT03589560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
Study NCT03589560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
Study NCT01901120 — intervention group
Intervention type: DRUG
Intervention: Betanis
Description: oral
Study NCT06199596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-s1 casein hydrolysate
Description: 150mg of Prelactium per capsule
Study NCT06199596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 150mg of Maltodextrin per capsule
Study NCT03868046 — intervention group
Intervention type: DRUG
Intervention: Treatment with immune checkpoint inhibitors.
Description: Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
Study NCT03868046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests.
Description: Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
Study NCT05307146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: macro/micro electrode recording
Description: intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
Study NCT00532701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + WB RBV for 48 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48
Study NCT00532701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + LD RBV for 24 weeks
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved
Study NCT02274961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-pantoprazole 10mg
Study NCT02795832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-5212372 1% w/w Ointment BID
Study NCT00776321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02795832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment BID
Study NCT01219569 — intervention group
Intervention type: DRUG
Intervention: propofol
Description: Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
Study NCT01219569 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: sevoflurane 1.5% and 2.5% end tidal in random sequence
Study NCT00753467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ 1b (Actimmune)
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
Study NCT00753467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study NCT02274961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00648037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
Study NCT00753467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-γ 1b and Adefovir dipivoxil combination
Description: IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Study NCT03298165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
Study NCT03298165 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: diode laser
Description: diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
Study NCT01317030 — intervention group
Intervention type: DEVICE
Intervention: Contact Lens Wear
Description: Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
Study NCT01317030 — intervention group
Intervention type: DEVICE
Intervention: Contact Lens Wear
Description: Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
Study NCT01317030 — intervention group
Intervention type: OTHER
Intervention: Non-Contact Lens Wear
Description: No intervention
Study NCT01699360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A, Tacrolimus, Sirolimus
Study NCT01482845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: a new kind of doxorubicin
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: traditional chemotherapy drug
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: traditional chemotherapy drug
Study NCT01482845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.